FRANKFURT, March 20 (Reuters) - Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from ...

Recent advances in drug discovery research have led to the development of numerous drug candidate compounds with high ...

Novartis has reached an agreement to buy a PI3K-targeting drug for breast cancer from Synnovation Therapeutics, paying a hefty $2 billion upfront for the asset, which is in phase 1/2 testing. The deal ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent ...

This activity was supported by Contract No. 200-2011-38807 (Task Order No. 0051) and Contract No. HHSN263201200074I (Task Order No. HHSN26300052) with the Centers for Disease Control and Prevention ...

A growing body of research has examined the IRA’s implications for pharmaceutical innovation. Much of this literature has focused on the potential impact on the number of new drug launches, 5, 6 but ...

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...

NCI has played, and should continue to play, an important role in the development of new cancer therapeutics. That role has changed and will continue to evolve as the basic science underlying cancer ...